Melanotan 1 vs Melanotan 2

Melanotan 1 is a synthetic linear tridecapeptide, a 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds selectively to the melanocortin-1 receptor (MC1R), the switch that drives pigment production in skin cells.

It is marketed as Scenesse and was approved by the FDA on October 8, 2019, the first treatment cleared for erythropoietic protoporphyria (EPP), a rare disorder that makes sunlight painful (FDA NDA review, accessdata.fda.gov). The approved form is a 16 mg controlled-release implant placed under the skin roughly every two months by a clinician.

Afamelanotide raises eumelanin, the dark protective pigment, largely independent of UV exposure. In the pivotal EPP trials, patients gained pain-free time in sunlight and tolerated the implant well across repeated dosing (Langendonk et al., N Engl J Med, 2015). The approved indication is EPP only. It is not sold or approved as a cosmetic tanning drug.

Melanotan 2 is a synthetic, cyclic and truncated melanocortin analog. Unlike its MC1R-selective cousin, it activates several melanocortin receptors at once: MC1R, MC3R, MC4R, and MC5R.

It was never submitted for FDA approval and has no approved medical use. It circulates on the grey market as a "research chemical" powder that buyers reconstitute and self-inject. People use it off-label for tanning and for libido, since MC4R activation drives sexual response.

Because it is unregulated, grey-market vials carry no guarantee of identity, purity, or actual peptide mass. If you are looking at a deeper protocol for the molecule most self-injectors actually hold, see the Melanotan 2 dosage protocol. MT-2 is also one of several peptides for libido that act on melanocortin receptors.

One mechanistic fact explains the entire gap between these two peptides: how many receptors each one switches on.

Both peptides upregulate tyrosinase, the enzyme that builds melanin inside pigment cells. The difference is how evenly that pigment lands.

Melanotan 1 produces slow, uniform darkening because MC1R activation spreads across the skin's melanocytes in a controlled way. The result is an even tan over two to four weeks.

Melanotan 2 tans faster but more unevenly. It darkens existing moles and freckles along with the surrounding skin, so pigment concentrates in spots rather than spreading smoothly. That mole-darkening effect is cosmetically uneven and clinically important, since changes in pigmented lesions are exactly what dermatologists watch for. For the broader picture of how pigment-active peptides interact with skin, see what peptides do for skin.

The safety story splits cleanly along the receptor line. Melanotan 1 is narrow and well-characterized in trials. Melanotan 2 is broad, unregulated, and carries a documented signal toward dangerous skin changes.

Melanotan 1 exists in one legal form: the Scenesse implant, a prescription product approved only for erythropoietic protoporphyria and administered in a clinic. It is not available for cosmetic tanning.

Melanotan 2 has no FDA approval at all. It is sold on the grey market as a research chemical, and regulators including the UK MHRA have issued public safety warnings against buying and injecting it. Possessing or using it sits in a regulatory grey zone that varies by country.

For where injectable peptides stand legally in 2026, see are peptides legal, and for the enforcement trend, the FDA peptide crackdown covers how agencies are treating unapproved injectables.

The dosing structures are not comparable, because one is a clinic product and the other is self-injected.

Melanotan 1's approved form is a single 16 mg controlled-release implant placed subcutaneously roughly every two months by a clinician (FDA NDA review, accessdata.fda.gov). There is no consumer dosing decision; the implant releases over weeks on its own.

Melanotan 2 in grey-market use follows a self-administered pattern of a loading phase followed by smaller maintenance injections. The detail belongs on a dedicated page rather than here, so for the full breakdown see the Melanotan 2 dosage protocol. If you reach the point of handling any injectable peptide, the mechanics in how to inject peptides cover sterile technique.

The two peptides attract different users for different reasons, and availability shapes the choice as much as preference.

People who get Melanotan 1 almost always get it through medical necessity. It treats EPP, it is prescription-only, and the implant is administered in a clinic. Someone who simply wants an even tan with minimal side effects would prefer it on paper, but cannot buy it for that purpose. Availability is the wall.

People choose Melanotan 2 because it is easy to obtain, tans fast, and produces a libido effect. The tradeoff is accepting an unapproved molecule, no dose verification, and the documented pigment and melanoma signal. The decision is usually access versus risk, not one peptide being objectively better.

Picture a typical grey-market routine. A user runs a Melanotan 2 loading protocol of roughly 0.5 mg daily for two weeks, then moves to maintenance injections. The vial carries no certificate of identity or dose, so the actual amount per injection is unknown.

Nausea hits early, which the pilot-study literature describes as a common, dose-dependent effect of Melanotan 2. Over the following weeks, two existing moles darken and a new pigmented spot appears on the back.

This is the decision point that matters. Because Melanotan 2 is documented in multiple case reports to precede melanoma and eruptive dysplastic nevi (Cousen et al., Br J Dermatol, 2009), any darkening, growth, or new lesion calls for a dermatologist, not a higher dose. Melanotan 1 avoids most of this because it acts only on MC1R, but it is prescription-only and not legally sold for cosmetic tanning.